Smartwatch with heart rate monitor icon on colorful diagonal striped background
Medtech Case Study

Patient Input Highlights Fit and Usability Gaps in a Vaginal Dryness Device

View Medtech Patient Engagement Library

Redesigning Vaginal Dryness Device to Address Fit and Usability Gaps

MV.Health develops men’s and women’s health devices that adapt to users’ bodies and deliver precise vibrations to support intimate wellness and improve sexual function. During the development of an at-home device to address vaginal dryness, the company received patient input late in the product’s development. As a result, MV.Health had to redesign the device to address fit and usability issues. 
 

Quick Facts

Organization Name: MV.Health

Organization Type: small medtech company (<50 employees)

Product Category: therapeutic device or technology

Regions(s) of Patient Engagement Activities: Europe: United Kingdom; North America: United States

Total Product Lifecycle Stage(s): Discovery/Preclinical, Clinical/Testing, Evaluation/Authorization, Adoption, Fundraising
 

 

Product Type(s)

medical devices: 

  • home-use device 
  • therapeutic device 

digital health technology: 

  • patient monitoring (sensors, etc.) 

Product Medical Specialty Area(s)

  • Obstetrical and gynecological  
     

Stakeholders

  • medtech company: internal discovery/research and development (R&D) teams 
  • medtech company: internal clinical affairs/R&D teams 
  • medtech company: internal regulatory affairs teams 
  • medtech company: internal market access teams 
  • medtech company: internal medical affairs teams 
  • medtech company: internal marketing teams 
  • medtech company: internal compliance teams 
  • investors (government, philanthropic, and private) 
     

Barriers or Obstacles Encountered

  • budget/financial constraints
  • timeline restrictions
  • insufficient infrastructure
  • challenges with reaching appropriate patient populations
     

Limitations to Patient Engagement Activities

At the outset of developing a vaginal dryness device (Legato), patient engagement was not intentionally deprioritized, but rather underestimated. As an early-stage medical device company, the team assumed that robust clinical literature, anatomical measurements, and clinician input would be sufficient to inform a universally effective design. Vaginal dryness is also a highly sensitive and stigmatized condition, which created perceived barriers around recruiting patients, discussing intimate symptoms openly, and identifying appropriate engagement pathways without established clinical partnerships in place. 

There were also practical constraints. At the time, the company lacked the infrastructure, processes, and funding to conduct structured patient engagement activities such as interviews, co-design sessions, or usability studies. The team believed that designing to published “average” anatomical dimensions would minimize risk and accelerate development, especially given regulatory and manufacturing timelines. In hindsight, this approach reflected a common industry bias toward data abstraction over lived experience. 

Additionally, there was concern about introducing delays or complexity into the development process, particularly around ethics approvals, patient safeguarding, and data protection for intimate health research. 

These factors contributed to a cautious, literature-led approach rather than direct engagement. The challenges made it clear that these assumptions were flawed. This experience highlighted that perceived barriers to patient engagement are often outweighed by the risks of exclusion, and it fundamentally changed the company’s approach to product development going forward.
 

Impact of Pursuing Limited, Absent, or Late Patient Engagement Activities

Avoiding early patient engagement during the initial development of the Legato device had tangible clinical, commercial, and operational consequences. 

By relying solely on published anatomical data and clinician assumptions, the team designed a first-generation product that theoretically fit most patients but, in practice, was too large for many and only suitable for outlier anatomies. This resulted in poor real-world fit, inconsistent outcomes, and reduced patient comfort. For the company, this led to measurable costs, including the need to pause commercialization, write off tooling and development work, and invest in a full product redesign. Development timelines were extended significantly, increasing R&D spending, and delaying market traction. 

Commercial confidence was also affected, requiring additional effort to rebuild trust with clinicians, partners, and early adopters. For patients, limited engagement meant delayed access to a solution that truly addressed their needs. Some early users experienced frustration or disappointment, reinforcing barriers around trust and adoption in an already stigmatized area of health. Clinicians were hesitant to recommend the device due to variable patient experiences, limiting integration into care pathways. Partners and stakeholders, including distributors and investors, faced uncertainty as product-market fit was reassessed. 

This experience underscored that late patient engagement introduces hidden costs, slows impact, and increases execution risk. By contrast, engaging patients early in the redesign led to a highly adaptable product with over 80% effectiveness, faster adoption, and stronger clinician endorsement.
 

Follow-on Corrective Actions

Following the challenges encountered with the first-generation Legato device, the team fundamentally restructured our R&D process to embed patient engagement as a core design input rather than a validation step. The immediate corrective action was to pause further commercialization and fully redesign the product with patients and clinicians involved from the outset. 

The team conducted structured engagement with a diverse group of patients experiencing vaginal dryness across different life stages, body types, and symptom severity, alongside clinicians who regularly treat these conditions. These interactions informed every aspect of the redesign, including overall size, flexibility, shape, material feel, and how the device adapts to different anatomies. Rather than designing to static anatomical averages, the team shifted to a body-adaptive approach that could accommodate natural variation and comfort preferences. 

The team also introduced iterative prototyping cycles, allowing patients and clinicians to provide real-time feedback on usability, comfort, and perceived effectiveness before finalizing the design. Internally, we formalized patient engagement checkpoints within our development pipeline, ensuring that future products could not progress without direct user validation. This process was supported by clearer governance around ethics, consent, and data handling for intimate health research. 

The impact of these corrective actions was measurable. The redesigned Legato device achieved high effectiveness in over 80% of users post-launch, stronger clinician confidence, and faster adoption. Most importantly, these learnings have now been applied across our broader product portfolio, shaping how we develop all future devices.